Oxford Cannabinoid Technologies Holdings Plc (OCTHF) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 London, 영국. 현재 CEO는 Clarissa Ann Sowemimo-Coker.
OCTHF 을(를) 보유 IPO 날짜 2021-10-20, 5 명의 정규직 직원, 에 상장 Other OTC, 시가총액 $3.05M.
Oxford Cannabinoid Technologies Holdings Plc, a pharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based prescription medicines. Its lead drug candidate is OCT461201, a selective CB2 receptor agonist in solid oral dosage form that is in pre-clinical development for use in the treatment of IBS-associated visceral pain, as well as neuropathic pain conditions, including post herpetic neuralgia. The company is also developing OCT130401, which is in pre-clinical development for the treatment of trigeminal neuralgia. Oxford Cannabinoid Technologies Holdings Plc was incorporated in 2017 and is headquartered in London, the United Kingdom.
